vs

Side-by-side financial comparison of FATE THERAPEUTICS INC (FATE) and Nano Labs Ltd (NA). Click either name above to swap in a different company.

Nano Labs Ltd is the larger business by last-quarter revenue ($2.7M vs $1.4M, roughly 2.0× FATE THERAPEUTICS INC). Nano Labs Ltd produced more free cash flow last quarter ($-8.4M vs $-112.0M).

Insys Therapeutics was an American specialty pharmaceutical company based in Chandler, Arizona in 1990. Its main product was Subsys, a sublingual liquid form of the drug fentanyl. Fentanyl is an extremely fast-acting and powerful opioid used to relieve breakthrough pain in cancer patients, and prescription of fentanyl in the US for such pain usually requires documented failure of more conservative therapies.

Weebit Nano is a public semiconductor IP company founded in Israel in 2015 and headquartered in Hod HaSharon, Israel. The company develops Resistive Random-Access Memory technologies. Resistive Random-Access Memory is a specialized form of non-volatile memory (NVM) for the semiconductor industry. The company's products are targeted at a broad range of NVM markets where persistence, performance, and endurance are all required. ReRAM technology can be integrated in electronic devices like weara...

FATE vs NA — Head-to-Head

Bigger by revenue
NA
NA
2.0× larger
NA
$2.7M
$1.4M
FATE
More free cash flow
NA
NA
$103.7M more FCF
NA
$-8.4M
$-112.0M
FATE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FATE
FATE
NA
NA
Revenue
$1.4M
$2.7M
Net Profit
$20.3M
Gross Margin
Operating Margin
Net Margin
754.5%
Revenue YoY
-26.4%
Net Profit YoY
37.9%
EPS (diluted)
$1.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FATE
FATE
NA
NA
Q4 25
$1.4M
$2.7M
Q3 25
$1.7M
Q2 25
$1.9M
$1.2M
Q1 25
$1.6M
Q4 24
$1.9M
Q3 24
$3.1M
Q2 24
$6.8M
$3.5M
Q1 24
$1.9M
Net Profit
FATE
FATE
NA
NA
Q4 25
$20.3M
Q3 25
$-32.3M
Q2 25
$-34.1M
$-985.5K
Q1 25
$-37.6M
Q4 24
Q3 24
$-47.7M
Q2 24
$-38.4M
$-8.0M
Q1 24
$-48.0M
Gross Margin
FATE
FATE
NA
NA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.1%
Q1 24
Operating Margin
FATE
FATE
NA
NA
Q4 25
Q3 25
-1995.1%
Q2 25
-1938.5%
-459.2%
Q1 25
-2534.1%
Q4 24
Q3 24
-1703.9%
Q2 24
-665.7%
-237.2%
Q1 24
-2652.9%
Net Margin
FATE
FATE
NA
NA
Q4 25
754.5%
Q3 25
-1852.4%
Q2 25
-1786.6%
-85.2%
Q1 25
-2309.5%
Q4 24
Q3 24
-1551.0%
Q2 24
-567.4%
-231.3%
Q1 24
-2493.7%
EPS (diluted)
FATE
FATE
NA
NA
Q4 25
$1.03
Q3 25
$-0.27
Q2 25
$-0.29
$-0.06
Q1 25
$-0.32
Q4 24
Q3 24
$-0.40
Q2 24
$-0.33
$-0.12
Q1 24
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FATE
FATE
NA
NA
Cash + ST InvestmentsLiquidity on hand
$203.7M
$4.9M
Total DebtLower is stronger
$24.5M
Stockholders' EquityBook value
$207.2M
$106.5M
Total Assets
$318.9M
$159.3M
Debt / EquityLower = less leverage
0.23×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FATE
FATE
NA
NA
Q4 25
$203.7M
$4.9M
Q3 25
$215.4M
Q2 25
$222.8M
$50.8M
Q1 25
$240.4M
Q4 24
$279.1M
Q3 24
$296.9M
Q2 24
$304.9M
$3.3M
Q1 24
$121.3M
Total Debt
FATE
FATE
NA
NA
Q4 25
$24.5M
Q3 25
Q2 25
$24.8M
Q1 25
Q4 24
Q3 24
Q2 24
$22.5M
Q1 24
Stockholders' Equity
FATE
FATE
NA
NA
Q4 25
$207.2M
$106.5M
Q3 25
$234.1M
Q2 25
$261.4M
$86.8M
Q1 25
$288.4M
Q4 24
$318.7M
Q3 24
$362.3M
Q2 24
$397.0M
$-5.1M
Q1 24
$426.1M
Total Assets
FATE
FATE
NA
NA
Q4 25
$318.9M
$159.3M
Q3 25
$343.7M
Q2 25
$371.6M
$206.4M
Q1 25
$398.7M
Q4 24
$440.7M
Q3 24
$495.0M
Q2 24
$528.8M
$51.2M
Q1 24
$569.9M
Debt / Equity
FATE
FATE
NA
NA
Q4 25
0.23×
Q3 25
Q2 25
0.29×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FATE
FATE
NA
NA
Operating Cash FlowLast quarter
$-106.1M
$-8.3M
Free Cash FlowOCF − Capex
$-112.0M
$-8.4M
FCF MarginFCF / Revenue
-8183.9%
-312.3%
Capex IntensityCapex / Revenue
434.8%
2.9%
Cash ConversionOCF / Net Profit
-0.41×
TTM Free Cash FlowTrailing 4 quarters
$-199.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FATE
FATE
NA
NA
Q4 25
$-106.1M
$-8.3M
Q3 25
$-24.4M
Q2 25
$-24.6M
$-7.1M
Q1 25
$-33.8M
Q4 24
$-122.9M
Q3 24
$-29.4M
Q2 24
$-32.3M
$-10.8M
Q1 24
$-33.4M
Free Cash Flow
FATE
FATE
NA
NA
Q4 25
$-112.0M
$-8.4M
Q3 25
$-26.6M
Q2 25
$-25.9M
$-7.2M
Q1 25
$-35.0M
Q4 24
$-123.6M
Q3 24
$-29.9M
Q2 24
$-32.4M
$-15.4M
Q1 24
$-33.4M
FCF Margin
FATE
FATE
NA
NA
Q4 25
-8183.9%
-312.3%
Q3 25
-1526.5%
Q2 25
-1360.7%
-620.3%
Q1 25
-2148.9%
Q4 24
-6645.4%
Q3 24
-973.1%
Q2 24
-477.8%
-443.4%
Q1 24
-1736.9%
Capex Intensity
FATE
FATE
NA
NA
Q4 25
434.8%
2.9%
Q3 25
126.5%
Q2 25
71.4%
7.2%
Q1 25
73.4%
Q4 24
39.2%
Q3 24
16.1%
Q2 24
0.8%
133.1%
Q1 24
4.5%
Cash Conversion
FATE
FATE
NA
NA
Q4 25
-0.41×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons